Cancer: The Road to Amiens

被引:86
作者
Stewart, David J. [1 ]
Kurzrock, Razelle [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX 77030 USA
关键词
CELL LUNG-CANCER; PHASE-II; PLUS; SURVIVAL; MULTICENTER; THERAPY; CHEMOTHERAPY; GEMCITABINE; COMBINATION; SORAFENIB;
D O I
10.1200/JCO.2008.18.9621
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:328 / 333
页数:6
相关论文
共 44 条
[1]  
[Anonymous], 2013, AVUTIA SI SARACIA NA
[2]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[3]   Teaching quality improvement - The devil is in the details [J].
Batalden, Paul ;
Davidoff, Frank .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (09) :1059-1061
[4]  
Bedell Cindi Holt, 2003, Clin J Oncol Nurs, V7, P5, DOI 10.1188/03.CJON.S6.5-9
[5]   We should desist using RECIST, at least in GIST [J].
Benjamin, Robert S. ;
Choi, Haesun ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Charnsangavej, Chuslip .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764
[6]  
Bennis W., 1994, On Becoming A Leader, V2nd
[7]  
Berton Pierre., 1986, Vimy
[8]   Uncommon tumors and exceptional therapies: paradox or paradigm? [J].
Braiteh, Fadi ;
Kurzrock, Razelle .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) :1175-1179
[9]  
Brave M, 2006, ONCOLOGY-NY, V20, P1401
[10]  
BUCKINGHAM M, 1999, BREAK ALL RULES